| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2012: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we made efforts for collection of the basic information and improvement of the fundamental technology for the development of the transcutaneous vaccine formulation using our original self-dissolving microneedle patch. Also, we focused on shortening for the transition period to the clinical trial and the manufacture study of the transcutaneous vaccine formulation by conducting clinical research to investigate safety and efficacy. Furthermore, we pushed forward with the screening of a promising candidate as adjuvant for transcutaneous vaccine formulations mainly on Toll-like receptor ligands and attempted to create the future-type transcutaneous influenza vaccine formulation capable of achieving stable efficacy based on the vaccine dose reduction, the vaccination frequency reduction, and the immune response reinforcement.
|
